Skip To Main Content
Xinrui Yin on Muck Rack

Xinrui Yin

As seen in: Frontiers, Frontiers in Medicine, Frontiers in Immunology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Xinrui

Contact Xinrui, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Modified frailty index versus risk analysis index for 30-day mortality after noncardiac surgery: a systematic review and meta-analysis

|
By Xinrui Yin, Shijia Du
| Frontiers in Medicine
Abstract Background: mFI and RAI are widely used in noncardiac surgical risk stratification, but they differ in content and data requirements. Because construct validity and outcome discrimination are distinct, we evaluated their prognostic discrimination for 30-day all-cause mortality without treating either instrument as a criterion-standard multidimensional frailty measure.
Open in Who Shared Issue with article?

Oral microbiome and lesion-associated microbiological findings in medication-related osteonecrosis of the jaw: a systematic review and evidence map

|
By Xinrui Yin, Shijia Du, Jun WAN
| Frontiers
SYSTEMATIC REVIEW article Front. Cell. Infect. Microbiol., 08 September 2026 Sec. Oral Microbes and Host Volume 16 - 2026 | https://doi.org/10.3389/fcimb.2026.1923000 Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.
Open in Who Shared Issue with article?

Agonistic anti-CD40 antibodies in patients with solid tumors: a systematic review and evidence map of clinical safety, with exploratory proportional synthesis

|
By Xinrui Yin, Shijia Du
| Frontiers in Immunology
Abstract Background: Agonistic anti-CD40 antibodies and related CD40 agonist biologics are being developed across multiple solid tumors using diverse biologic formats, delivery routes, and combination regimens. Safety is central to their clinical development but remains difficult to interpret because high-grade adverse events in combination settings may reflect partner therapies, and safety outcomes are reported inconsistently.
Open in Who Shared Issue with article?
See all 5 articles